Cardurion Pharmaceuticals

About Cardurion Pharmaceuticals

Cardurion is a next-generation cardiovascular company focused on transforming the treatment of cardiovascular disease by translating world-class expertise in cardiovascular signaling pathways into groundbreaking therapeutics for patients. They aim to address unmet needs through innovative clinical programs, strategic portfolio approaches, and partnerships.

Products & Services

PDE9 Inhibition Program:A clinical program targeting heart failure (both HFrEF and HFpEF) with a potential new foundational treatment to improve efficacy alongside guideline-directed medical therapy.

CaMKII Inhibition Program:A pioneering clinical program targeting rare arrhythmias like catecholaminergic polymorphic ventricular tachycardia (CPVT) and more common cardiovascular diseases such as heart failure and atrial fibrillation, by regulating calcium signaling and cardiac function.

Specialties

Cardiovascular Disease Treatment PDE9 Inhibition CaMKII Inhibition Drug Discovery Precision Medicine Adaptive Trial Designs

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 260000000 MR: - FA: $260 million FAN: 260000000	D: 2024-07-16 FD: 2024-07-16	12 investors

Series B Latest

2024-07-16

$260.0M

12 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

E

Eric Olson

Chairman, Scientific Advisory Board; Professor and Chairman, Department of Molecular Biology, UT Southwestern Medical Center

M

Mark Anderson

Executive Vice President for Medical Affairs, Dean of the Division of the Biological Sciences, Dean of the Pritzker School of Medicine, University of Chicago

D

David Kass

Professor of Medicine and Cardiology

D

Douglas Mann

Professor of Medicine and Cardiology

S

Silvia G. Priori

Professor of Cardiology, University of Pavia; Scientific Director and Director of the Cardiology Division, Istituti Clinici Scientifici (ICS) Maugeri; Director of the Molecular Cardiology Laboratories, Centro National De Investigaciones Cardiovasculares Carlos III

J

James Udelson

Chairman, Clinical Advisory Board

View 22 more team members with Pro

Unlock Full Team Directory

Recent News